Plain-English translation of NCT07193277 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication originally used for stroke recovery, to see if it can help improve memory and thinking problems in older adults with focal epilepsy. Currently, seizure medications control seizures well in many patients, but they don't help much with cognitive symptoms—and sometimes even make them worse. This study will enroll 220 older adults to find out whether the medication can protect brain function and improve daily cognitive abilities when added to their regular seizure treatment.
Memory and thinking problems affect 40–60% of older people with focal epilepsy and seriously impact quality of life, yet current seizure medications don't address these cognitive symptoms. This trial exists to explore whether this neuroprotective medication—which works by improving blood flow to the brain, reducing inflammation, and protecting brain cells—could fill that treatment gap.
You likely qualify if…
You likely don't qualify if…
You would take soft capsules of the medication (or matching placebo) by mouth three times daily before meals for 48 weeks while continuing your regular seizure medication. During this time, you would undergo detailed memory and thinking assessments at multiple visits, including tests of recall, attention, and daily functioning. You would also have regular safety check-ups with blood tests and vital sign monitoring, with a 24-hour emergency contact system available if you need support.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China